{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T13:18:28Z","timestamp":1783430308678,"version":"3.54.6"},"reference-count":33,"publisher":"IMR Press","issue":"6","license":[{"start":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T00:00:00Z","timestamp":1782345600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100007129","name":"Natural Science Foundation of Shandong Province","doi-asserted-by":"crossref","award":["ZR2022QH059"],"award-info":[{"award-number":["ZR2022QH059"]}],"id":[{"id":"10.13039\/501100007129","id-type":"DOI","asserted-by":"crossref"}]},{"name":"The Second Hospital of Shandong University","award":["2022YP57"],"award-info":[{"award-number":["2022YP57"]}]},{"name":"Special Scientific Research and Academic Activity Project for the High-Quality Development of Hospital Pharmacy in Shandong Province Pharmacy Association","award":["SDSYXH-46-2025-13"],"award-info":[{"award-number":["SDSYXH-46-2025-13"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmazie"],"abstract":"<jats:p>Objective:To analyze data from the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS) database to characterize the adverse effects of caplacizumab, including associated adverse events (AEs) and safety signals in real-world clinical practice. and obtain evidence to support the rational use of this drug in the treatment of thrombotic thrombocytopenic purpura (TTP).Methods:Postmarketing AE reports associated with caplacizumab were retrieved from the FAERS database. Safety signals were identified using four disproportionality analysis methods: the reporting odds ratio, proportional reporting ratio, Bayesian Confidence Propagation Neural Network (BCPNN), and multi-item gamma Poisson shrinker. The Weibull distribution was used to analyze the onset time of AEs, and subgroup analyses were performed according to sex, age group, and reporter type.Results:In total, 1144 reports involving caplacizumab were analyzed. Most AEs were nonserious. Among the 401 reports with documented onset times, 162 (40.4%) described AEs occurring within 7 days of administration. Common bleeding-related events (e.g., epistaxis, gingival bleeding, gastrointestinal hemorrhage, heavy menstrual bleeding, and vaginal hemorrhage) were consistent with product labeling. Decreases in platelet count and in disintegrin and metalloproteinase with thrombospondin type 1 motif 13 (ADAMTS13) activity were interpreted as manifestations of the underlying disease (acquired TTP) rather than drug-induced AEs. Newly identified safety signals included contusion, injection site pain, injection site bruising, injection site erythema, injection site haemorrhage, pruritus and rash.Conclusions:These findings underscore the importance of pharmacovigilance and postmarketing surveillance for caplacizumab. Clinicians should closely monitor bleeding events and injection site reactions during treatment. To ensure the safe use of caplacizumab, the mechanisms underlying these potential signals should be elucidated, and targeted monitoring strategies should be developed.<\/jats:p>","DOI":"10.31083\/pharmazie52100","type":"journal-article","created":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T12:56:33Z","timestamp":1783428993000},"source":"Crossref","is-referenced-by-count":0,"title":["Postmarketing Safety Concerns With Caplacizumab: A Real-World Pharmacovigilance Study Based on the FDA Adverse Event Reporting System Database"],"prefix":"10.31083","volume":"81","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-1514-9497","authenticated-orcid":true,"given":"Juan","family":"Shao","sequence":"first","affiliation":[{"name":"Department of Pharmacy, The Second Qilu Hospital of Shandong University, 250033 Jinan, Shandong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0236-8119","authenticated-orcid":true,"given":"Jing","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Jinan Shizhong People\u2019s Hospital, 250000 Jinan, Shandong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-3482-0660","authenticated-orcid":true,"given":"Hong-yan","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Zibo Municipal Hospital, 255400 Zibo, Shandong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5509-2331","authenticated-orcid":true,"given":"Xiao-xia","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The Second Qilu Hospital of Shandong University, 250033 Jinan, Shandong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"16242","published-online":{"date-parts":[[2026,6,25]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","unstructured":"Joly BS, Coppo P, Veyradier A. Thrombotic thrombocytopenic purpura. Blood. 2017; 129: 2836\u20132846.","DOI":"10.1182\/blood-2016-10-709857"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"Cataland SR, Coppo P, Scully M, L\u00e4mmle B. Thrombotic thrombocytopenic purpura: 100 years of research on Moschcowitz syndrome. Blood. 2024; 144: 1143\u20131152.","DOI":"10.1182\/blood.2023022277"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"Scully M, Cataland SR, Peyvandi F, Coppo P, Kn\u00f6bl P, Kremer Hovinga JA, et al. Caplacizumab Treatment for Acquired Thrombotic Thrombocytopenic Purpura. The New England Journal of Medicine. 2019; 380: 335\u2013346.","DOI":"10.1056\/NEJMoa1806311"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"Matsumoto M, Fujimura Y, Wada H, Kokame K, Miyakawa Y, Ueda Y, et al. Diagnostic and treatment guidelines for thrombotic thrombocytopenic purpura (TTP) 2017 in Japan. International Journal of Hematology. 2017; 106: 3\u201315.","DOI":"10.1007\/s12185-017-2264-7"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"Kn\u00f6bl P. Thrombotic thrombocytopenic purpura. Memo. 2018; 11: 220\u2013226.","DOI":"10.1007\/s12254-018-0429-6"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"Scully M, Carter MA, Subhan MO. Thrombotic thrombocytopenic purpura: celebrating 25 years of ADAMTS13. Blood. 2026.  (online ahead of print)","DOI":"10.1182\/blood.2025030791"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"Peyvandi F, Scully M, Kremer Hovinga JA, Cataland S, Kn\u00f6bl P, Wu H, et al. Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura. The New England Journal of Medicine. 2016; 374: 511\u2013522.","DOI":"10.1056\/NEJMoa1505533"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"Zheng XL, Al-Housni Z, Cataland SR, Coppo P, Geldziler B, Germini F, et al. 2025 focused update of the 2020 ISTH guidelines for management of thrombotic thrombocytopenic purpura. Journal of Thrombosis and Haemostasis : JTH. 2025; 23: 3711\u20133732.","DOI":"10.1016\/j.jtha.2025.06.002"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"Wang G, Su L, Liu Y, Yang X, Li Y, Mei Q, et al. Cardiovascular toxicity of tisagenlecleucel in children and adolescents: analysis of spontaneous reports submitted to FAERS. Frontiers in Immunology. 2025; 16: 1499143.","DOI":"10.3389\/fimmu.2025.1499143"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"Tu J, Zhang C, Qiu Y, Zhang H, Zheng J, Xie S, et al. Rotigotine safety in real-world settings: a pharmacovigilance study using FAERS data. BMC Pharmacology & Toxicology. 2025; 26: 72.","DOI":"10.1186\/s40360-025-00911-5"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"Lv L, Wu X, Ren Y, Guo Y, Wang H, Li X. Postmarketing safety evaluation of pemetrexed using FAERS and JADER databases. Scientific Reports. 2025; 15: 18738.","DOI":"10.1038\/s41598-025-02426-9"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"Liu M, Yin P, Fan R, Zhang G, Zhao K. A real-world pharmacovigilance study of Certolizumab pegol based on FAERS database. Scientific Reports. 2025; 15: 28529.","DOI":"10.1038\/s41598-025-13502-5"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"Coppo P, Bubenheim M, Benhamou Y, V\u00f6lker L, Brinkk\u00f6tter P, K\u00fchne L, et al. Caplacizumab use in immune-mediated thrombotic thrombocytopenic purpura: an international multicentre retrospective Cohort study (The Capla 1000+ project). EClinicalMedicine. 2025; 82: 103168.","DOI":"10.1016\/j.eclinm.2025.103168"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"Roose E, Vidarsson G, Kangro K, Verhagen O, Mancini I, Desender L, et al. Anti-ADAMTS13 autoantibodies against cryptic epitopes in immunemediated thrombotic thrombocytopenic purpura. Thrombosis and Haemostasis. 2018; 118: 1729\u20131742.","DOI":"10.1055\/s-0038-1669459"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"le Besnerais M, Veyradier A, Benhamou Y, Coppo P. Caplacizumab: a change in the paradigm of thrombotic thrombocytopenic purpura treatment. Expert Opinion on Biological Therapy. 2019; 19: 1127\u20131134.","DOI":"10.1080\/14712598.2019.1650908"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"Hollifield AL, Arnall JR, Moore DC. Caplacizumab: an anti-von Willebrand factor antibody for the treatment of thrombotic thrombocytopenic purpura. American Journal of Health-system Pharmacy. 2020; 77: 1201\u20131207.","DOI":"10.1093\/ajhp\/zxaa151"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"Reese JA, Muthurajah DS, Kremer Hovinga JA, Vesely SK, Terrell DR, George JN. Children and adults with thrombotic thrombocytopenic purpura associated with severe, acquired Adamts13 deficiency: comparison of incidence, demographic and clinical features. Pediatric Blood & Cancer. 2013; 60: 1676\u20131682.","DOI":"10.1002\/pbc.24612"},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"Wu J, Li N, Gu J, Shen Y, Qiu L, Zhu L. Post-marketing safety evaluation of Vortioxetine: A decade-long pharmacovigilance study based on the FAERS database. Journal of Affective Disorders. 2025; 379: 586\u2013593.","DOI":"10.1016\/j.jad.2025.03.007"},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"George JN. How I treat patients with thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Blood. 2000; 96: 1223\u20131229.","DOI":"10.1182\/blood.V96.4.1223"},{"key":"ref20","doi-asserted-by":"publisher","unstructured":"Duggan S. Caplacizumab: First Global Approval. Drugs. 2018; 78: 1639\u20131642.","DOI":"10.1007\/s40265-018-0989-0"},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"Scully M. Refractoriness in TTP: challenges and solutions. Blood. 2026; 147: 2418-2420.","DOI":"10.1182\/blood.2026033269"},{"key":"ref22","doi-asserted-by":"publisher","unstructured":"Scully M, de la Rubia J, Pavenski K, Metjian A, Kn\u00f6bl P, Peyvandi F, et al. Long-term follow-up of patients treated with caplacizumab and safety and efficacy of repeat caplacizumab use: Post-HERCULES study. Journal of Thrombosis and Haemostasis : JTH. 2022; 20: 2810\u20132822.","DOI":"10.1111\/jth.15892"},{"key":"ref23","doi-asserted-by":"publisher","unstructured":"Pishko AM, Li A, Cuker A. Immune Thrombotic Thrombocytopenic Purpura: A Review. JAMA. 2025; 334: 517\u2013529.","DOI":"10.1001\/jama.2025.3807"},{"key":"ref24","doi-asserted-by":"publisher","unstructured":"Jestin M, Benhamou Y, Schelpe AS, Roose E, Prov\u00f4t F, Galicier L, et al. Preemptive rituximab prevents long-term relapses in immune-mediated thrombotic thrombocytopenic purpura. Blood. 2018; 132: 2143\u20132153.","DOI":"10.1182\/blood-2018-04-840090"},{"key":"ref25","doi-asserted-by":"publisher","unstructured":"Khan S, Landry K, Umyarova E. Caplacizumab treatment for acquired refractory thrombotic thrombocytopenic purpura. British Journal of Haematology. 2020; 191: e44\u2013e46.","DOI":"10.1111\/bjh.16977"},{"key":"ref26","doi-asserted-by":"publisher","unstructured":"Miyakawa Y, Imada K, Ichikawa S, Uchiyama H, Ueda Y, Yonezawa A, et al. The efficacy and safety of caplacizumab in Japanese patients with immune-mediated thrombotic thrombocytopenic purpura: an open-label phase 2\/3 study. International Journal of Hematology. 2023; 117: 366\u2013377.","DOI":"10.1007\/s12185-022-03495-6"},{"key":"ref27","doi-asserted-by":"publisher","unstructured":"Jim\u00e9nez M, Bobillo S, Pons V, S\u00e1nchez C, P\u00e9rez A, Molero A, et al. Real-world data with the use of caplacizumab in the treatment of acquired thrombotic thrombocytopenic purpura: A single-center with homogeneous treatment experience. Transfusion. 2022; 62: 2363\u20132369.","DOI":"10.1111\/trf.17111"},{"key":"ref28","doi-asserted-by":"publisher","unstructured":"Soto-Mora JA, G\u00f3mez-Espitia LM, Lasalvia P, Castellanos Moreno CA, Casallas Vanegas CA, Londo\u00f1o Guti\u00e9rrez SA. Effectiveness and safety of caplacizumab in acquired thrombotic thrombocytopenic purpura: health technology assessment and classification according to the methodology established in Colombia. International Journal of Technology Assessment in Health Care. 2023; 39: e48.","DOI":"10.1017\/S0266462323000442"},{"key":"ref29","doi-asserted-by":"publisher","unstructured":"Borogovac A, Reese JA, Gupta S, George JN. Morbidities and mortality in patients with hereditary thrombotic thrombocytopenic purpura. Blood Advances. 2022; 6: 750\u2013759.","DOI":"10.1182\/bloodadvances.2021005760"},{"key":"ref30","doi-asserted-by":"publisher","unstructured":"Mangoni AA, Jackson SH. Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications. British journal of clinical pharmacology. 2004; 57: 6-14.","DOI":"10.1046\/j.1365-2125.2003.02007.x"},{"key":"ref31","doi-asserted-by":"publisher","unstructured":"McLean AJ, Le Couteur DG. Aging biology and geriatric clinical pharmacology. Pharmacological reviews. 2004; 56: 163-184.","DOI":"10.1124\/pr.56.2.4"},{"key":"ref32","doi-asserted-by":"publisher","unstructured":"Zhou X, Yang G, Zeng X, Wang L, Xiang J, Zhao J, et al. Dupilumab and the potential risk of eosinophilic pneumonia: case report, literature review, and FAERS database analysis. Frontiers in Immunology. 2024; 14: 1277734.","DOI":"10.3389\/fimmu.2023.1277734"},{"key":"ref33","doi-asserted-by":"publisher","unstructured":"Ma J, Cai J, Chen H, Feng Z, Yang G. Cardiovascular Adverse Events Associated with Tumor Necrosis Factor-Alpha Inhibitors: A Real-World Pharmacovigilance Analysis. Journal of Atherosclerosis and Thrombosis. 2024; 31: 1733\u20131747.","DOI":"10.5551\/jat.64767"}],"container-title":["Die Pharmazie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.imrpress.com\/journal\/Pharmazie\/81\/6\/10.31083\/Pharmazie52100","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T12:57:09Z","timestamp":1783429029000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.imrpress.com\/journal\/Pharmazie\/81\/6\/10.31083\/Pharmazie52100"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,25]]},"references-count":33,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026]]}},"alternative-id":["S0031-7144(26)03101-0"],"URL":"https:\/\/doi.org\/10.31083\/pharmazie52100","relation":{},"ISSN":["0031-7144","3053-691X"],"issn-type":[{"value":"0031-7144","type":"print"},{"value":"3053-691X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,25]]},"article-number":"52100"}}